All In Biotech

Drug Trial Radar · NCT06128733

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age).

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,215 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,215

Actual

Start

Oct 31, 2023

Primary completion

Aug 27, 2025

Study completion Aug 27, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 25 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.

Conditions

  • Meningococcal Immunisation
  • Healthy Volunteers

Interventions

  • Pentavalent Meningococcal ABCYW vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)

  • MenACYW conjugate vaccineBiological

    Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

  • Meningococcal group B vaccineBiological

    Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)

  • Meningococcal group B vaccineBiological

    Pharmaceutical form:Suspension for injection in pre-filled syringe-Route of administration:Intramuscular (IM)

  • Meningococcal group B vaccineBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular (IM)

  • MenACYW conjugate vaccineBiological

    Pharmaceutical form:Powder and solvent for solution for injection-Route of administration:Intramuscular (IM)

  • PlaceboBiological

    Pharmaceutical form:Solution for injection in vial-Route of administration:Intramuscular (IM)

  • MenABCYW conjugate vaccineBiological

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular (IM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with immediate adverse events (AEs)Time frame: Within 30 minutes after each vaccination
  2. Number of participants with solicited injection site reactions or systemic reactionsTime frame: Within 7 days after each vaccination
  3. Number of participants with unsolicited AEsTime frame: Within 30 days after each vaccination
  4. Number of participants with serious adverse events (SAEs)Time frame: From baseline up to 12 months
  5. Number of participants with medically attended adverse events (MAAEs)Time frame: From baseline up to 12 months
  6. Number of participants with out-of-range biological test resultsTime frame: Before each vaccination up to 7 days after primary vaccination visits in the sentinel cohorts (the first 5 participants enrolled in each vaccine group) of each age group
  7. hSBA meningococcal serogroups A, C, W, and Y vaccine seroresponse pre-dose and 1 month after the second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
  8. hSBA meningococcal serogroups A, C, W, and Y antibody titers pre-dose and 1 month after the second dose in adolescent participantsTime frame: Day 211 (for Group 1 to 7)
  9. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroups A, C, W and Y pre-dose and 1 month after the second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 31 Day 211 (for Group 1 to 7)
  10. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each of serogroups A, C, W, and Y in adolescent participantsTime frame: Day 01 (pre-dose) Day 211 (for Group 1 to 7)
  11. hSBA meningococcal serogroup B seroresponse pre-dose and 1 month after second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
  12. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:4 pre-dose 1 and 1 month post-second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
  13. Percentage of Participants With Meningococcal Antibody Titers against meningococcal serogroup B (reference MenB strains) ≥ 1:8 pre-dose 1 and 1 month post-second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
  14. Geometric mean titers (GMTs) of Antibodies against Meningococcal Serogroup B (reference MenB strains) pre-dose 1 and 1 month post-second dose in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)
  15. Percentage of participants with hSBA titers more or equal to lower limit of quantification (LLOQ) against each and all serogroups B (reference MenB strains) in adolescent participantsTime frame: Day 01 (pre-dose) and Day 211 (for Group 1 to 7)

Locations

47 sites in 2 countries. Site status is shown where the registry gives one.

  • Accel Research Site - Birmingham Clinical Research Unit- Site Number : 8400080

    Birmingham, Alabama

  • Lakeview Clinical Research Site Number : 8400029

    Guntersville, Alabama

  • Alliance for Multispecialty Research- Phoenix- Site Number : 8400056

    Tempe, Arizona

  • Harrisburg Family Medical Center Site Number : 8400070

    Harrisburg, Arkansas

  • Smart Cures Clinical Research Site Number : 8400072

    Anaheim, California

  • Hope Clinical Research, LLC- Site Number : 8400001

    Canoga Park, California

  • Apex Research Group Site Number : 8400071

    Fair Oaks, California

  • Velocity Clinical Research-Washington DC Site Number : 8400102

    Washington D.C., District of Columbia

  • Accel Clinical Research-Deland Clinical Research Unit- Site Number : 8400081

    DeLand, Florida

  • SIMEDHealth, LLC- Site Number : 8400045

    Gainesville, Florida

  • Accel Research Sites-St. Petersburg-Largo- Site Number : 8400082

    Largo, Florida

  • South Florida Research Organization Site Number : 8400086

    Medley, Florida

  • Life Arc Research-Miami Site Number : 8400094

    Miami, Florida

  • Charisma Medical and Research center Site Number : 8400097

    Miami Lakes, Florida

  • Accel Research - Nona Pediatric Center Site Number : 8400079

    Orlando, Florida

  • Ormond Beach Clinical Research- Site Number : 8400073

    Ormond Beach, Florida

  • Palm Harbor Dermatology- Site Number : 8400030

    Tampa, Florida

  • PAS Research Site Number : 8400032

    Tampa, Florida

  • VICIS Clinical Research-Tampa Site Number : 8400065

    Tampa, Florida

  • Leavitt Clinical Research-Idaho Falls- Site Number : 8400075

    Idaho Falls, Idaho

  • Snake River Research, PLLC- Site Number : 8400100

    Idaho Falls, Idaho

  • AES Peoria- Site Number : 8400090

    Peoria, Illinois

  • AMR Evansville Site Number : 8400062

    Evansville, Indiana

  • AMR - Newton- Site Number : 8400104

    Newton, Kansas

  • ~Kentucky Pediatics / Adult Research- Site Number : 8400009

    Bardstown, Kentucky

  • Michael W. Simon, MD, PSC- Site Number : 8400026

    Lexington, Kentucky

  • Vida Clinical Studies Site Number : 8400084

    Dearborn Heights, Michigan

  • Vida Clinical Studies- Site Number : 8400084

    Dearborn Heights, Michigan

  • Be Well Clinical Studies- Site Number : 8400077

    Lincoln, Nebraska

  • Alivation Research (Primary Care) Site Number : 8400046

    Lincoln, Nebraska

  • Quality Clinical Research, Inc.- Site Number : 8400074

    Omaha, Nebraska

  • Velocity Clinical Research, Omaha- Site Number : 8400066

    Omaha, Nebraska

  • Velocity Clinical Research-Albuquerque- Site Number : 8400101

    Albuquerque, New Mexico

  • Prime Global Research, Inc. Site Number : 8400043

    The Bronx, New York

  • Monroe Biomedical Research - Site Number : 8400099

    Monroe, North Carolina

  • SPICA Clinical Research Site Number : 8400098

    Columbia, South Carolina

  • Coastal Carolina Research Center - N Charleston- Site Number : 8400050

    North Charleston, South Carolina

  • Tribe Clinical Research at Parkside Pediatrics-Five Forks Site Number : 8400049

    Simpsonville, South Carolina

  • Pediatric Clinical Trials Tullahoma- Site Number : 8400020

    Tullahoma, Tennessee

  • New Horizon Medical Group-Houston Site Number : 8400069

    Houston, Texas

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.